Abstract
Gynecomastia is the benign proliferation of glandular tissue affecting more than half of men to some degree throughout their lives (Niewoehner and Nuttal 1984). The etiology is multifactorial; however, it involves a decrease in systemic androgens, increase in estrogen, or an enhanced tissue estrogen sensitivity (Georgiadis et al. 1994). Hormonal imbalances may be secondary to systemic illnesses, hypogonadism, diet, lifestyle choices, or certain medications; in all circumstances, treatment begins with conservative approaches aimed at addressing the underlying pathology with lifestyle modifications, consultation with an endocrinologist, and assessment of current medications (Di Lorenzo et al. 2005). Patients with recalcitrant disease may offer a variety of invasive approaches; more localized cases are amenable to liposuction, while for true symptomatic gynecomastia, surgery is accepted as a standard of care (Fruhstorfer and Malata 2003). While severe cases may require full mastectomies with free nipple grafts, this option is often reserved for the highest grades given scar burden and risk of nipple loss (Johnson and Murad 2009). In patients who are not surgical candidates, or who are placed on DES or feminizing hormones, radiation therapy can play a role in prevention or treatment. With the changing landscape of hormonal therapy for prostate cancer, radiotherapy is now less commonly used in these indications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham P, Acharya S (2010) Current and emerging treatment options for Graves’ hyperthyroidism. Ther Clin Risk Manag 6:29–40
Alfthan O, Holsti LR (1969) Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol 3(3):183–187
Allahabadia A, Daykin J, Holder RL et al (2000) Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 85(3):1038–1042
Beling U, Einhorn J (1961) Incidence of hypothyroidism and recurrences following I131 treatment of hyperthyroidism. Acta Radiol 56(4):275–288
Blahd WH, Hays MT (1972) Graves’ disease in the male: a review of 241 cases treated with an individually calculated dose of sodium iodide I 131. Arch Intern Med 129(1):33–40
Brown JS, Rubenfeld S (1974) Irradiation in preventing gynecomastia induced by estrogens. Urology 3(1):51–53
Burke G (1969) Hypothyroidism after treatment with sodium iodide I 131. JAMA 210(6):1051
Cevallos JL, Hagen GA, Maloof F et al (1974) Low-dosage 131I therapy of thyrotoxicosis (diffuse goiters). N Engl J Med 290(3):141–143
Chou JL, Easley JD, Feldmeier JJ, Rauth VA, Pomeroy TC (1988) Effective radiotherapy in palliating mammalgia associated with gynecomastia after DES therapy. Int J Radiat Oncol Biol Phys 15(3):749–751
Cook S, Rodriguez-Antunez A (1973) Pre-estrogen irradiation of the breast to prevent gynecomastia. Am J Roentgenol Radium Ther Nucl Med 117(3):662–663
Corvalan JG, Gill WM Jr, Egleston TA, Rodriguez-Antunez A (1969) Irradiation of the male breast to prevent hormone produced gynecomastia. Am J Roentgenol Radium Ther Nucl Med 106(4):839–840
Di Lorenzo G, Autorino R, Perdona S, De Placido S (2005) Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol 6(12):972–979
Donovan JK, Turtle JR (1966) The results of radioiodine therapy in thyrotoxicosis. Med J Aust 2(6):271–272
Dunn JT, Chapman EM (1964) Rising incidence of hypothyroidism after radioactive-iodine therapy in thyrotoxicosis. N Engl J Med 271(20):1037–1042
Edsmyr F, Einhorn J (1966) Complications in radioiodine treatment of hyperthyroidism. Acta Radiol Ther Phys Biol 4(1):49–54
Fass D, Steinfeld A, Brown J, Tessler A (1986) Radiotherapeutic prophylaxis of estrogen-induced gynecomastia: a study of late sequela. Int J Radiat Oncol Biol Phys 12(3):407–408
Feibush JS, Sherman AA (1968) Low incidence of hypothyroidism following radioiodine therapy. Bronx-Lebanon Hospital Center, New York
Franco J, Coppler M, Kovaleski B (1970) Propranolol and 131I in the treatment of diffuse thyroid hyperplasia with hyperthyroidism. J Nucl Med 11(5):219–220
Fruhstorfer BH, Malata CM (2003) A systematic approach to the surgical treatment of gynaecomastia. Br J Plast Surg 56(3):237–246
Georgiadis E, Papandreou L, Evangelopoulou C et al (1994) Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 21(6):579–587
Goolden AW, Fraser TR (1969) Effect of pretreatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J 3(5668):443–444
Gronich N, Lavi I, Rennert G et al (2020) Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid 30(2):243–250
Hagen GA, Ouellette RP, Chapman EM (1967) Comparison of high and low dosage levels of 131I in the treatment of thyrotoxicosis. N Engl J Med 277(11):559–562
Hamburger JI, Paul S (1968) When and how to use higher 131I doses for hyperthyroidism. N Engl J Med 279(25):1361–1365
Hayek A, Chapman EM, Crawford JD (1970) Long-term results of treatment of thyrotoxicosis in children and adolescents with radioactive iodine. N Engl J Med 283(18):949–953
Hertz S, Roberts A, Salter WT (1942) Radioactive iodine as an indicator in thyroid physiology. IV. The metabolism of iodine in Graves’ disease. J Clin Invest 21(1):25–29
Jackson GL (1971) Radioiodine therapy of thyrotoxicosis. Am J Roentgenol 112(4):726–731
Johnson RE, Murad MH (2009) Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 84(11):1010–1015
Joll CA (1933) X rays and radium in Graves’s disease. Br Med J 1(3764):338
Kaipainen WJ, Vuopala U, Salokannel J et al (1970) Low dose radioactive iodine in the treatment of hyperthyroidism. Ann Clin Res 2(2):122
Kempster C (1933) X rays and radium in Graves’s disease. Br Med J 1(3764):338
Larsson L-G, Sundbom C-M (1962) Roentgen irradiation of the male breast. Acta Radiol 58(4):253–256
Leslie WD, Ward L, Salamon EA et al (2003) A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab 88(3):978–983
Lewitus Z, Lubin E, Rechnic J et al (1971) Treatment of thyrotoxicosis with 125I and 131I. Semin Nucl Med 1(4):411–421
McDougall JR, Greig WR (1972) Combined carbimazole-131I treatment for thyrotoxicosis. Scott Med J 17(2):57–61
Metso S, Jaatinen P, Huhtala H et al (2004) Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 61(5):641–648
Mizokami T, Hamada K, Maruta T et al (2020) Long-term outcomes of radioiodine therapy for juvenile Graves disease with emphasis on subsequently detected thyroid nodules: a single institution experience from Japan. Endocr Pract 26(7):729–737
Neal FE (1965) Results of radioactive iodine treatment in thyrotoxicosis. Nucl Med Suppl 2:303+
Niewoehner CB, Nuttal FQ (1984) Gynecomastia in a hospitalized male population. Am J Med 77(4):633–638
Nofal MM (1966) Treatment of hyperthyroidism with sodium iodide I 131. JAMA 197(8):605
Ozen H, Akyol F, Toktas G et al (2010) Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? J Urol 184(2):519–524
Perdona S, Autorino R, De Placido S et al (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6(5):295–300
Reinwein D, Miss H, Horster FA et al (1969) Late results of fractionated radioiodine therapy. Follow-up studies of hyperthyroidism after 2 to 11 years. Ger Med Mon 14(5):234–238
Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280(4):347–355. https://doi.org/10.1001/jama.280.4.347
Ross DS, Burch HB, Cooper DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10):1343–1421
Sachs BA, Siegel E, Kass S et al (1972) Radioiodine therapy of thyrotoxicosis the Montefiore experience. Am J Roentgenol 115(4):698–705
Saenger EL, Thoma GE, Tompkins EA (1968) Incidence of leukemia following treatment of hyperthyroidism: preliminary report of the Cooperative Thyrotoxicosis Therapy follow-up study. JAMA 205(12):855–862
Safa AM, Schumacher OP, Rodriguez-Antunez A (1975) Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 292(4):167–171
Säterborg NE, Einhorn J (1966) Fractionated 131I therapy in large toxic goitres. Acta Endocrinol 51(1):7–14
Smith RN, Wilson GM (1967) Clinical trial of different doses of 131-I in treatment of thyrotoxicosis. Br Med J 1(5533):129
Srinivasan V, Miree J Jr, Lloyd FA (1972) Bilateral mastectomy and irradiation in the prevention of estrogen induced gynecomastia. J Urol 107(4):624–625
Tezcan UP, Frelick RW, Meckelnburg RL (1967) Low dose therapy of hyperthyroidism. Wilmington Medical Center, Wilmington, DE
Thjodleifsson B (1975) A study of Graves’ disease in Iceland. Acta Med Scand 198(1–6):309–314
Tunbridge WM, Harsoulis P, Goolden AW (1974) Thyroid function in patients treated with radioactive iodine for thyrotoxicosis. Br Med J 3(5923):89–92
Tyrrell CJ, Payne H, Tammela TL et al (2004) Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 60(2):476–483
Van Poppel H, Tyrrell CJ, Haustermans K et al (2005) Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur Urol 47(5):587–592
Viherkoski M, Lamberg BA, Hernberg CA et al (1970) Treatment of toxic nodular and diffuse goitre with radioactive iodine. Acta Endocrinol 64(1):159–170
Wang J, Qin L (2016) Radioiodine therapy versus antithyroid drugs in Graves’ disease: a meta-analysis of randomized controlled trials. Br J Radiol 89(1064):20160418
Waterfall NB, Glaser MG (1979) A study of the effects of radiation on prevention of gynaecomastia due to oestrogen therapy. J Clin Oncol 5(3):257–260
Widmark A, Fossa SD, Lundmo P et al (2003) Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 61(1):145–151
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Safran, T., Juneau, D. (2023). Endocrinological Disorders. In: Roberge, D., Donaldson, S.S. (eds) Radiation Therapy of Benign Diseases. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_372
Download citation
DOI: https://doi.org/10.1007/174_2022_372
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-35516-5
Online ISBN: 978-3-031-35517-2
eBook Packages: MedicineMedicine (R0)